A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 267 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukaemia with... December 9, 2022 A Summer Poem August 20, 2021 Adding Apalutamide to Perioperative ADT Associated with Better Outcomes of Radical... June 3, 2026 Cómo comenzar a hacer ejercicio en el hogar durante el tratamiento... January 18, 2023 Load more HOT NEWS How Breast Cancer Risk Assessment Tools Work How Financial Toxicity Can Impact Cancer Caregivers and Where to Find... Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR...
